$ARMP News

Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States

Armata Pharmaceuticals Stock Slides after Pentagon Funding Fuels Phase 3 Push for Anti-Bacterial Program

Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development

HC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $15 Price Target

Armata Pharmaceuticals Receives Additional $3.7M In Non-dilutive Funds From US Department Of War For Phase 3 Development Program For AP-SA02

Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates

Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02

Armata Pharmaceuticals Receives FDA Breakthrough Therapy Designation For Its Intravenously Administered Staphylococcus Aureus Multi-Phage Product Candidate AP-SA02

Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials

Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update

Armata Pharmaceuticals Q2 EPS $(0.27) Beats $(0.45) Estimate, Sales $2.510M Beat $420.000K Estimate

Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar?

Why Is Armata Pharma Stock Gaining Monday?

Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02

Armata Pharma Promotes David House To CFO

Armata Announces Significant Clinical, Regulatory, Manufacturing And Operational Progress Supporting Advancement Of AP-SA02 Toward Planned Phase 3 Superiority Study For Adjunct Treatment Of Complicated Bacteremia

Armata Pharmaceuticals: Promising Phage Platform, But Phase 3 Is Everything

Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia

Armata Pharma Receives Agreement From FDA On Agreed Initial Pediatric Study Plan